Antiretrovirals Control HIV and Leave the Gut Unrepaired

Antiretroviral therapy solves the problem it was designed for. It suppresses viral replication, often below detection, and it has turned HIV into a condition people live with for decades. What it does not do is repair the gut. Early infection strips the intestinal epithelium and the immune tissue beneath it, and that damage persists through years of successful treatment, leaking bacterial products into circulation and sustaining the chronic inflammation that drives much of the excess morbidity people with HIV still carry.

A group at UC Davis has identified a bacterial metabolite that repairs it, and shown that giving it alongside antiretrovirals does something the drugs alone do not. The molecule is 10-hydroxystearic acid, a modified fatty acid made by Lactiplantibacillus plantarum, and it appears to be part of how the gut community responds to its own inflammation.

Why it matters: Gut inflammation and epithelial disruption are among the stronger predictors of HIV-associated illness in people whose virus is well controlled. A therapy aimed at the barrier rather than the virus addresses the part of the disease that suppression leaves behind.

What breaks, and why suppression does not fix it

The damage happens fast and early. HIV and its macaque counterpart SIV destroy the CD4 T cells concentrated in gut-associated lymphoid tissue within the first weeks of infection, before most people know they are infected. The epithelial layer those cells help maintain becomes permeable, and bacterial products that should stay in the lumen cross into circulation, where they keep the immune system activated indefinitely.

Antiretrovirals arrest replication but do not reverse that architecture, which is why people with fully suppressed virus can still carry elevated inflammatory markers and the cardiovascular and metabolic risk that accompanies them. The gut is also where much of the latent reservoir sits, so a damaged, inflamed intestine is not merely a side issue but plausibly part of why the infection persists.

From a metabolite to a receptor to the chromatin

The mechanistic chain is worked out to an unusual degree for a microbiome study. Using X-ray crystallography alongside transcriptomics, the team showed that 10-HSA binds PPARalpha directly, a nuclear receptor governing lipid metabolism, rather than acting through some diffuse anti-inflammatory effect. Activating it induces lipid metabolism and mitochondrial regeneration, and that metabolic shift feeds into an epigenetic one: histone crotonylation, a chromatin modification that depends on the products of fatty acid metabolism. Epithelial renewal follows.

Crucially, PPARalpha is the pathway HIV suppresses. The team showed that HIV antigens shut down PPARalpha signalling, disrupt the metabolic programmes downstream of it, and impair epithelial repair, and that 10-HSA restores both the receptor's activity and its transcriptional network. The virus and the metabolite act on the same node in opposite directions.

The human observation that anchors it

The most persuasive evidence is not from the animals. Long-term non-progressors, the rare people who control HIV for years without treatment, turn out to have heightened PPARalpha signalling and downstream transcriptional activity compared with therapy-naive individuals. That is a correlation in humans rather than an experiment, and it means the pathway the metabolite activates is the pathway already elevated in people whose bodies handle the infection best.

In SIV-infected macaques, combining 10-HSA with antiretroviral therapy repaired epithelial barrier structure and function, reduced mucosal inflammation, expanded Firmicutes populations and restored microbial diversity. It also accelerated viral suppression, which is the result that goes beyond the stated aim. As Kramer and colleagues argue in Nature Microbiology, this suggests that revitalizing mucosal immunity may present a more effective strategy for improving viral remission than reactivating exhausted host immune cells. That is a pointed comparison. Checkpoint inhibitors against PD-1 and CTLA-4, the fashionable approach to waking up exhausted immune cells in HIV, have neither eradicated virus nor proved well tolerated.

What the study can't say yet

The intervention arm is macaques. SIV in rhesus macaques is the best available model of HIV pathogenesis and it is a model, differing in host genetics, viral kinetics and the composition of the gut community that produces and responds to the metabolite in the first place. The human data here are transcriptional comparisons, not treatment.

Accelerated viral suppression is also the finding most in need of a mechanism. The authors attribute it to restored mucosal immunity, which is plausible and consistent with the gut being the major reservoir of susceptible cells, but a faster decline in viral load under combined therapy has several candidate explanations that this design does not separate. Nor does anything here address the durable question, which is whether repairing the barrier changes the long-term inflammatory burden that shortens lives. A macaque experiment cannot speak to decades of human disease.

Quick questions

Could someone take a probiotic instead? Not established. The active agent is a specific metabolite that L. plantarum makes under particular inflammatory conditions, and the study administered the compound rather than the bacterium.

Why does gut damage persist when the virus is suppressed? Because the epithelium and its underlying immune tissue are destroyed early, and antiretrovirals stop viral replication without instructing damaged tissue to regenerate.

What's the one-line takeaway? A fatty acid made by gut bacteria activates PPARalpha, the repair pathway HIV shuts down and long-term non-progressors keep switched on, and giving it with antiretrovirals in macaques repaired the gut and sped viral suppression.